Epizyme Appoints Dr. Shefali Agarwal as Chief Medical Officer
23 juil. 2018 07h00 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the appointment of Dr. Shefali...
Epizyme Announces Date of Second Quarter 2018 Financial Results and Business Update Conference Call
19 juil. 2018 07h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report its second...
Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)
15 juin 2018 05h30 HE
|
Epizyme, Inc.
Consistently High Responses in Patients with an EZH2 Activating MutationDurable Clinical Responses and Progression-Free Survival Observed in Patients With or Without an EZH2 Activating MutationCompany...
Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO
03 juin 2018 09h00 HE
|
Epizyme, Inc.
Disease Control Rate of 51 Percent Achieved at 12 WeeksRepresents the First Reported Clinical Data of an EZH2 Inhibitor in Patients with Relapsed/Refractory Malignant Mesothelioma CAMBRIDGE, Mass.,...
Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data
01 juin 2018 07h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a...
Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress
17 mai 2018 09h13 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that new data from two Phase 2 trials...
Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
08 mai 2018 07h30 HE
|
Epizyme, Inc.
Enrollment of Patients Completed in Multiple Tazemetostat Combination Studies EU Orphan Designations Received for Tazemetostat Conference Call to be Held on May 17, 2018 at 9:30 a.m. ET CAMBRIDGE,...
Epizyme Announces First Quarter 2018 Financial Reporting Date and Upcoming Conference Call
01 mai 2018 07h30 HE
|
Epizyme, Inc.
First Quarter 2018 Financial Results to be Announced May 8, 2018 Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials CAMBRIDGE, Mass.,...
Epizyme Provides Update Regarding Tazemetostat Clinical Program
23 avr. 2018 16h45 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that U.S.-based enrollment of new...
Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
09 avr. 2018 18h45 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today its first-in-human data on the...